AERAS-402

BIOLOGICAL5 trials

Sponsors

Aeras, University of Oxford

Conditions

HIV InfectionsTuberculosisTuberculosis Paediatrics

Phase 1

Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

CompletedNCT01683773

University of OxfordTuberculosis

Start: 2012-09-30End: 2014-08-31Updated: 2014-09-17

A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402

CompletedNCT02375256

AerasTuberculosis

Start: 2009-10-31End: 2013-12-31Updated: 2015-03-03

A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB

CompletedNCT02430506

AerasTuberculosis

Start: 2008-09-30End: 2010-07-31Updated: 2016-04-27

Phase 2

Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

CompletedNCT01017536

AerasHIV Infections, Tuberculosis

Start: 2009-12-31End: 2012-05-31Updated: 2016-09-09

Unknown Phase

Phase II, AERAS-402 in BCG Vaccinated Infants

Active, not recruitingPACTR201203000306280

AerasTuberculosis Paediatrics

Start: 2010-05-07Target: 4192Updated: 2026-01-27

Related Papers

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

PLoS ONE2015-11-0340 citations